LifeMD股價因與諾和諾德公司繼續Wegovy合作關係而上漲

英為財情

2025/06/26

Investing.com -- LifeMD Inc (NASDAQ:LFMD)股價上漲4.3%，此前諾和諾德公司(Novo Nordisk)(NYSE:NVO)宣佈將繼續與該遠程醫療提供商合作，通過NovoCare藥房為患者提供FDA批准的Wegovy。諾和諾德公司確認其與LifeMD和Ro的合作關係將繼續，因為這家制藥巨頭正在擴大患者獲取其減肥藥Wegovy的渠道。該公司還宣佈將從...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2546618753"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546618753\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546618753?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-06-26 23:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546618753","market":"sh","top_or_hot":-1,"title":"LifeMD股價因與諾和諾德公司繼續Wegovy合作關係而上漲","media":"英為財情","content":"<div>\n<p>Investing.com --  LifeMD  Inc (NASDAQ:LFMD)股價上漲4.3%，此前諾和諾德公司(Novo Nordisk)(NYSE:NVO)宣佈將繼續與該遠程醫療提供商合作，通過NovoCare藥房為患者提供FDA批准的Wegovy。\n諾和諾德公司確認其與LifeMD和Ro的合作關係將繼續，因為這家制藥巨頭正在擴大患者獲取其減肥藥Wegovy的渠道。該公司還宣佈將從...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2862472\">網頁鏈接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LifeMD股價因與諾和諾德公司繼續Wegovy合作關係而上漲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeMD股價因與諾和諾德公司繼續Wegovy合作關係而上漲\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">英為財情</strong><span class=\"h-time small\">2025-06-26 23:43</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Investing.com --  LifeMD  Inc (NASDAQ:LFMD)股價上漲4.3%，此前諾和諾德公司(Novo Nordisk)(NYSE:NVO)宣佈將繼續與該遠程醫療提供商合作，通過NovoCare藥房為患者提供FDA批准的Wegovy。\n諾和諾德公司確認其與LifeMD和Ro的合作關係將繼續，因為這家制藥巨頭正在擴大患者獲取其減肥藥Wegovy的渠道。該公司還宣佈將從...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2862472\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2862472\">英為財情</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"諾和諾德","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2862472","article_id":"2546618753","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2862472","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2546618753","pubTimestamp":1750952580,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com --  LifeMD  Inc 股價上漲4.3%，此前諾和諾德公司宣佈將繼續與該遠程醫療提供商合作，通過NovoCare藥房為患者提供FDA批准的Wegovy。諾和諾德公司確認其與LifeMD和Ro的合作關係將繼續，因為這家制藥巨頭正在擴大患者獲取其減肥藥Wegovy的渠道。此消息發布之際，諾和諾德公司最近終止了與LifeMD競爭對手Hims & Hers Health的合作。從7月1日開始，諾和諾德公司將為Wegovy推出新的自費價格，為每月USD 299，該優惠有效期至2025年7月31日。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NVO":"诺和诺德","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4007":"制药"},"translate_title":"LifeMD stock rises on continued Wegovy partnership with Novo Nordisk","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Investing.com --  LifeMD  Inc (NASDAQ:LFMD)股價上漲4.3%，此前諾和諾德公司(Novo Nordisk)(NYSE:NVO)宣佈將繼續與該遠程醫療提供商合作，通過NovoCare藥房為患者提供FDA批准的Wegovy。\n諾和諾德公司確認其與LifeMD和Ro的合作關係將繼續，因為這家制藥巨頭正在擴大患者獲取其減肥藥Wegovy的渠道。該公司還宣佈將從2025年7月1日起與WeightWatchers展開新的合作，後者將與CenterWell藥房合作管理處方藥的配送。\n這家丹麥製藥商強調，這些合作關係基於\"他們致力於為患有慢性疾病的患者提供安全有效的醫療治療\"。此消息發布之際，諾和諾德公司最近終止了與LifeMD競爭對手Hims & Hers Health的合作。\n從7月1日開始，諾和諾德公司將為Wegovy推出新的自費價格，為每月USD 299，該優惠有效期至2025年7月31日。此優惠面向Wegovy節省計劃的新用户，或此前未通過NovoCare藥房配藥的患者。7月之後，自費患者的價格將上漲至每月USD 499。\n諾和諾德公司已在全國範圍內全面提供FDA批准的各劑量Wegovy，並繼續對銷售未經授權的\"司美格魯肽\"產品的實體採取法律行動。該公司已在34個州對非法營銷或銷售仿製藥的實體提起了近120起訴訟。\n\"我們理解人們選擇接受護理的方式正在發生變化，\"諾和諾德公司美國運營執行副總裁Dave Moore表示。\"我們將繼續尋求並建立與共享我們價值觀的公司的協議，並完善幫助改善患者獲取我們FDA批准藥物的舉措。\"\n\n本文由人工智能協助翻譯。更多信息，請參見我們的使用條款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}